The role of pharmacogenetics in the treatment of osteosarcoma

被引：57

作者：

Vos, Hanneke I. ^{[1
]}

Coenen, Marieke J. H. ^{[2
]}

Guchelaar, Henk-Jan ^{[3
]}

te Loo, Dunja Maroeska W. M. ^{[4
]}

机构：

[1] Radboud Univ Nijmegen, Med Ctr, Dept Pediat, Lab Pediat Oncol, POB 9101, NL-6500 HB Nijmegen, Netherlands

[2] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, Dept Human Genet, POB 9101, NL-6500 HB Nijmegen, Netherlands

[3] Leiden Univ, Med Ctr, Dept Clin Pharm & Toxicol, POB 9600, NL-2300 RC Leiden, Netherlands

[4] Radboud Univ Nijmegen, Med Ctr, Dept Pediat, Dept Pediat Hematol & Oncol, POB 9101, NL-6500 HB Nijmegen, Netherlands

来源：

DRUG DISCOVERY TODAY | 2016年 / 21卷 / 11期

关键词：

ANTHRACYCLINE-INDUCED CARDIOTOXICITY; CISPLATIN-INDUCED OTOTOXICITY; HIGH-GRADE OSTEOSARCOMA; S-TRANSFERASE POLYMORPHISMS; ERCC2 GENE POLYMORPHISMS; INDUCED HEARING-LOSS; DRUG-METABOLIZING-ENZYMES; INDUCED LIVER TOXICITY; BONE-TUMOR; INDIVIDUAL SENSITIVITY;

D O I：

10.1016/j.drudis.2016.06.022

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In osteosarcoma, large variation is observed in the efficacy and toxicity of chemotherapeutic drugs among similarly treated patients. Treatment optimization using predictive factors or algorithms is of importance, because there has been a lack of improvement of treatment outcome and survival for decades. The outcome of cancer treatment is influenced by the genome, thus studying genetic variants involved in the efficacy and toxicity of the chemotherapeutic drugs used in the treatment of osteosarcoma could be an opportunity to optimize current treatments and improve our understanding of the individual's drug response in osteosarcoma patients. This review discusses the current insights in the pharmacogenetics of the treatment response of osteosarcoma patients regarding efficacy and toxicity, and implications for future research and treatment.

引用

页码：1775 / 1786

页数：12

共 50 条

[1] The role of pharmacogenetics in osteosarcoma
Hagleitner, M.
Coenen, M.
Gelderblom, H.
Vos, H.
De Bont, E.
Van der Graaf, W.
Hoogerbrugge, P.
Guchelaar, H. J.
Loo, M. Te
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S690 - S690
[2] PHARMACOGENETICS OF MICRORNAS IN OSTEOSARCOMA
Bilbao-Aldaiturriaga, N.
L'pez-L'pez, E.
Martin-Guerrero, I.
Gutierrez-Camino, A.
Serrasesumaga, L.
Zalacain-Diez, M.
Garcia-Orad, A.
Patino-Garcia, A.
PEDIATRIC BLOOD & CANCER, 2013, 60 : 25 - 26
[3] Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma
Hattinger, Claudia Maria
Serra, Massimo
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2015, 11 (09) : 1449 - 1463
[4] PHARMACOGENETICS OF METHOTREXATE IN PAEDIATRIC OSTEOSARCOMA
Hegyi, M.
Csordas, K.
Eipel, O.
Csagoly, E.
Erdelyi, D. J.
Semsei, A. F.
Kovacs, G. T.
PEDIATRIC BLOOD & CANCER, 2013, 60 : 86 - 86
[5] Pharmacogenetics of chemotherapy treatment response and -toxicities in patients with osteosarcoma: a systematic review
Hurkmans, Evelien G. E.
Brand, Annouk C. A. M.
Verdonschot, Job A. J.
te Loo, D. Maroeska W. M.
Coenen, Marieke J. H.
BMC CANCER, 2022, 22 (01)
[6] Pharmacogenetics of chemotherapy treatment response and -toxicities in patients with osteosarcoma: a systematic review
Evelien G. E. Hurkmans
Annouk C. A. M. Brand
Job A. J. Verdonschot
D. Maroeska W. M. te Loo
Marieke J. H. Coenen
BMC Cancer, 22
[7] Is there a role for pharmacogenetics in the treatment of panic disorder?
Caldirola, Daniela
Perna, Giampaolo
PHARMACOGENOMICS, 2015, 16 (08) : 771 - 774
[8] THE ROLE OF PHARMACOGENETICS IN THE TREATMENT OF DIABETES MELLITUS
Topic, Elizabeta
JOURNAL OF MEDICAL BIOCHEMISTRY, 2014, 33 (01) : 58 - 70
[9] Is there a role for pharmacogenetics in the treatment of anorexia nervosa?
Smith, Sarah
Woodside, Blake
PHARMACOGENOMICS, 2016, 17 (13) : 1381 - 1383
[10] Pharmacogenetics of methotrexate therapy in pediatric osteosarcoma
不详
PHARMACOGENOMICS, 2009, 10 (04) : 517 - 517

← 1 2 3 4 5 →